


maripoc



Technology

3D immunoassay reaction on the surface of a
microparticle



- HiTech antigen test
- Automated and easy to use
- Laboratory quality at the point-of-care

TPX technology

maripOC® utilizes the TPX (Two-Photon Excitation) assay technique for highly sensitive and extremely specific antigen detection. It is a proprietary technology of the Finnish Company ArcDia International Ltd., the developer and manufacturer of maripOC®.

High sensitivity and specificity

maripOC® provides the best antigen detection sensitivity at the point-of-care. The superior specificity is the unique feature of the maripOC® technique. It results from the use of the sandwich immunoassay principle.

maripOC® is unique

Specificity is further improved by the use of 3 µm polystyrene microparticles as the solid reaction phase. Laser-excited fluorescence of individual microparticles is measured one at the time. Also the fluorescence signal of the surrounding matrix is recorded. Finally a sophisticated data reduction algorithm returns the quantitative test result.

The TPX technology brings antigen testing to the 3D level. The unique technology is easy to use, efficient and accurate. maripOC® detection is automated and separation-free. The process can be applied to various sample materials.

Hänninen P. et al. (2000) A New Microvolume Technique for Bioaffinity Assays Using Two-Photon Excitation. Nat Biotechnol. 18(5):548-550.



www.linkedin.fi/in/maripoc



www.twitter.com/ArcDialtd

ArcDia International Ltd.

www.maripoc.com



Made in Finland



maripoc



Each pathogen specific assay is carried out in an **individual well** of the test plate

- Reagents are dried to the well bottoms
- Rapid identification in 15-20 minutes
- Closed-well detection



Two-photon excitation with a **laser**

Fluorescent detection through the bottom of the **test plate**

Performance

| Test | maripOC® compared to | Sensitivity | Specificity | N |
|-----------------------------|--------------------------------|----------------------------------|-------------|-----|
| PCR | | | | |
| Respi | Influenza A virus | 92.3% | 99.8% | 899 |
| | Influenza B virus | 88% | 100% | 192 |
| | RSV | 89% | 100% | 158 |
| Bacterial culture | | | | |
| Pharyn | Group A streptococci | Pharyn 150% Quick StrepA 100% | 100% | 219 |
| Immunochromatography | | | | |
| CDI | <i>C. difficile</i> GDH | 100% | 98.8% | 188 |
| | <i>C. difficile</i> toxins A/B | > 100% | 100% | 188 |

Combine rapidity and lab level performance with maripOC®!

Thomas E. et al. 29th ECCMID 2019, Amsterdam, Netherlands. Abstract and poster #P0114.
 Sanbonmatsu-Gómez S. et al. (2015) Diagn Microbiol Infect Dis. 83:252-256.
 Ivaska L. et al. (2013) J Clin Virol. 57:136-140.
 Vakkila J. et al. (2015) J Clin Microbiol. 53:2079-2083.

